Clinical trials: Degenerative Conditions, Neurologic
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.
- Trial name
- NCT05673109
- Testing
- AC176
- Where
- 5 sites in China
- Volunteers
- 8 people
- Sponsor
- Accutar Biotechnology Inc
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Parkinson's Disease
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
- Trial name
- NCT02071134
- Testing
- Deep Brain Stimulation (DBS)
- Where
- 87 sites in United States, Argentina and 13 more
- Volunteers
- 1,500 people
- Sponsor
- Boston Scientific Corporation
Parkinson Disease
Opicapone Treatment Initiation Open-Label Study
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with…
- Trial name
- OPTI-ON (NCT04787965)
- Testing
- Opicapone
- Where
- 6 sites in United States
- Volunteers
- 239 people
- Sponsor
- Neurocrine Biosciences
Multiple System Atrophy (MSA), Parkinson's Disease (PD)
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
- Trial name
- NCT07604116
- Testing
- SST001
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Synusight Biotech (Shanghai) Co., Ltd.
Parkinson's Disease, L-dopa Induced Dyskinesia
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
- Trial name
- NCT00888004
- Testing
- AFQ056
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis
Dry Age-related Macular Degeneration, Vision Impairment and Blindness
Vision Improvement for Legally Blind Dry AMD Patients
This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.
- Trial name
- NCT04875234
- Testing
- Clear-K Low Vision Aid Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Alzheimer's Disease
Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer's disease…
- Trial name
- NCT00100334
- Testing
- PPI-1019 (APAN)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Alzheimer's Disease
Mifepristone as Adjunctive Therapy in Alzheimer's Disease
The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
- Trial name
- NCT00105105
- Testing
- Mifepristone
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Corcept Therapeutics
Lambert Eaton Myasthenic Syndrome
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
- Trial name
- NCT01377922
- Testing
- Amifampridine Phosphate
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 38 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD.
- Trial name
- NCT04339413
- Testing
- Gantenerumab
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
A 48-month open label multi-centered extension study to evaluate the long-term safety, tolerability and efficacy of E2007 in patients with Parkinson's Disease with "wearing off" motor fluctuations and "on" period Dyskinesias.
- Trial name
- NCT01634360
- Testing
- Perampanel
- Volunteers
- 185 people
- Sponsor
- Eisai Inc.
Parkinson's Disease, HIV Infections
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS).
- Trial name
- NCT00990379
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Salena Killion
Tuberous Sclerosis Complex
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
- Trial name
- NCT05604170
- Testing
- Ganaxolone
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 117 people
- Sponsor
- Marinus Pharmaceuticals
Parkinson's Disease
Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease
The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).
- Trial name
- NCT01016470
- Testing
- VIUSID/ALZER
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Amyotrophic Lateral Sclerosis
A Study of IPL344 in the Treatment of ALS Patients
This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALS (NCT03652805)
- Testing
- IPL344
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Immunity Pharma Ltd.
Generalized Myasthenia Gravis
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on…
- Trial name
- NCT07622342
- Testing
- SHR-2173 injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Amyotrophic Lateral Sclerosis
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin).
- Trial name
- NCT03068754
- Testing
- Acthar
- Where
- 69 sites in United States, Argentina and 5 more
- Volunteers
- 143 people
- Sponsor
- Mallinckrodt
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.